We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca set the tone for the future of SGLT2 diabetes medicines in May with Farxiga's heart-helping FDA approval in patients with or without diabetes.